While the literature consistently shows the beneficial effects of HDAC inhibitors on AD-like pathology in mouse models of AD, it should be noted that a few reports have also reported the lack of effects of a pan-specific HDAC inhibitor in transgenic AD mice. The gene discussed is HDAC9; the disease is Alzheimer disease.